A US$2.5bn AI drug alliance is taking shape, but what have Insilico and Bora actually agreed?
Insilico Medicine and Bora Pharmaceuticals propose an AI drug alliance worth over US$2.5 billion, but definitive agreements remain pending.
Pharma & Biotech
Pharma & Biotech
Insilico Medicine’s AI-originated IPF drug enters Phase 3, but the hardest test begins now
Find out how Insilico Medicine’s AI-originated rentosertib is entering Phase 3 testing for idiopathic pulmonary fibrosis.
Pharma & Biotech
Insilico Medicine secures Takeda collaboration to advance AI-designed drug candidates
Discover how Takeda’s $600 million Insilico Medicine collaboration could reshape AI drug discovery, candidate design and clinical translation.
Pharma & Biotech
Why Insilico’s $2.5bn SK Biopharmaceuticals deal could reshape AI drug discovery
Find out how Insilico and SK Biopharmaceuticals are using AI to target neuroimmune CNS disorders in a $2.5B drug discovery pact.
Features & Analysis
Are autonomous labs quietly turning biopharma researchers into scientific strategists?
Autonomous labs can run experiments faster. The bigger shift is what happens when biopharma researchers stop executing and start directing.
Pharma & Biotech
Insilico Medicine’s AI-designed anemia therapy begins Phase I testing in collaboration with TaiGen
Insilico Medicine and TaiGen advance AI-designed anemia drug ISM4808 into Phase I trials. Discover what this means for CKD therapy and AI drug discovery.
Pharma & Biotech
Can lightweight AI models replace massive drug discovery systems? Insilico Medicine and Liquid AI think so
Insilico Medicine and Liquid AI unveil a lightweight AI model for drug discovery. Learn how smaller foundation models could reshape pharmaceutical research.
Pharma & Biotech
How Insilico Medicine’s ISM8969 could unlock a new class of neuroinflammatory drugs
Insilico’s AI-designed drug ISM8969 enters Phase 1 for Parkinson’s disease. Find out what this NLRP3 candidate could mean for CNS drug development.
Pharma & Biotech
Insilico, Hygtia Therapeutics to co-develop brain-penetrant NLRP3 inhibitor ISM8969 for CNS diseases
Clinical-stage biotechnology company Insilico Medicine (HKEX: 3696) and Hygtia Therapeutics, a Shenzhen Pengfu Fund–backed startup under Fosun Health Capital, have entered into an exclusive co-development and licensing agreement to jointly advance ISM8969, a novel brain-penetrant NLRP3 inhibitor for central nervous system diseases. The deal grants 50-50 worldwide rights to both companies, with Insilico eligible to
Pharma & Biotech
Inside Insilico Medicine’s CKD push: AI-driven ISM4808 heads to Greater China with TaiGen
Insilico Medicine has licensed its AI-discovered oral PHD inhibitor ISM4808 to TaiGen Biotechnology for exclusive development and commercialization in the Greater China region, including Mainland China, Hong Kong, Macau, and Taiwan. The deal follows Investigational New Drug clearance in China in 2023 and positions TaiGen to bring the asset into clinical trials targeting anemia associated